Clinical summary
Summary
This is a non-randomised, open-label study investigating the effects of different regimens of chemotherapy in people with newly diagnosed stage II-IV diffuse anaplastic Wilm's tumours (DAWT) or relapsed favourable histology Wilm's Tumours (FHWT). Participants will DAWT and standard-risk relapsed FHWT will receive the UH-3 chemotherapy regimen, which includes vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan. Participants with high- and very-high risk FHWT will receive the ICE/Cyclo/Tropo chemotherapy regimen, which includes ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan. All treatments will be administered intravenously (via IV).Conditions
This trial is treating patients with Wilm's tumour.
Cancer
Urinary System
Age
>30
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
National Cancer Institute (NCI), Children's Oncology Group
Scientific Title
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)